Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA:688553)
19.12
+0.45 (2.41%)
Feb 3, 2026, 3:00 PM CST
SHA:688553 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 975.28 | 1,085 | 926.02 | 1,490 | 1,820 | 1,358 |
Other Revenue | 9.01 | 9.01 | 1.06 | 3.27 | 3.44 | 6.55 |
| 984.29 | 1,094 | 927.08 | 1,493 | 1,824 | 1,364 | |
Revenue Growth (YoY) | -12.10% | 18.05% | -37.92% | -18.12% | 33.68% | 92.94% |
Cost of Revenue | 188.78 | 187.58 | 132.75 | 180.12 | 160.19 | 120.91 |
Gross Profit | 795.51 | 906.8 | 794.32 | 1,313 | 1,664 | 1,243 |
Selling, General & Admin | 465.78 | 511.56 | 437.58 | 810.82 | 972.32 | 771.98 |
Research & Development | 334.32 | 327.72 | 340.76 | 356.19 | 248.21 | 88.77 |
Other Operating Expenses | -5.19 | 6.57 | 6.72 | 7.83 | 9.57 | 5.34 |
Operating Expenses | 794.7 | 845.82 | 787.93 | 1,176 | 1,230 | 865.56 |
Operating Income | 0.8 | 60.98 | 6.39 | 136.66 | 433.49 | 377.72 |
Interest Expense | -9.09 | -12.4 | -6.7 | -1.18 | -1.06 | -1.84 |
Interest & Investment Income | 43.96 | 50.23 | 79.73 | 91.18 | 20.16 | 13.4 |
Currency Exchange Gain (Loss) | -0.78 | -0.78 | 3.33 | -0.13 | -1.1 | -1.45 |
Other Non Operating Income (Expenses) | 4.8 | 0.66 | 1.39 | -5.16 | -4.17 | 0.49 |
EBT Excluding Unusual Items | 39.69 | 98.69 | 84.13 | 221.37 | 447.31 | 388.32 |
Gain (Loss) on Sale of Investments | -36.65 | 239.86 | 6.44 | 2.33 | 6.16 | - |
Gain (Loss) on Sale of Assets | -0.41 | -0.3 | - | -0.03 | -0.02 | -0.82 |
Asset Writedown | -1.46 | -9.6 | - | - | - | - |
Other Unusual Items | 22.19 | 21.05 | 41.58 | 14.72 | 24.25 | 8.95 |
Pretax Income | 23.36 | 349.7 | 132.15 | 238.39 | 477.7 | 396.46 |
Income Tax Expense | -16.7 | 33.8 | -7.18 | -10.6 | 31.84 | 54.63 |
Earnings From Continuing Operations | 40.06 | 315.9 | 139.33 | 248.99 | 445.86 | 341.82 |
Minority Interest in Earnings | 7.17 | 9.49 | 0.45 | - | - | 1.5 |
Net Income | 47.23 | 325.39 | 139.79 | 248.99 | 445.86 | 343.32 |
Net Income to Common | 47.23 | 325.39 | 139.79 | 248.99 | 445.86 | 343.32 |
Net Income Growth | -83.02% | 132.78% | -43.86% | -44.16% | 29.87% | 94.03% |
Shares Outstanding (Basic) | 424 | 423 | 424 | 422 | 372 | 361 |
Shares Outstanding (Diluted) | 424 | 423 | 424 | 422 | 372 | 361 |
Shares Change (YoY) | 0.62% | -0.24% | 0.37% | 13.58% | 2.81% | - |
EPS (Basic) | 0.11 | 0.77 | 0.33 | 0.59 | 1.20 | 0.95 |
EPS (Diluted) | 0.11 | 0.77 | 0.33 | 0.59 | 1.20 | 0.95 |
EPS Growth | -83.13% | 133.33% | -44.07% | -50.83% | 26.32% | - |
Free Cash Flow | 12.14 | 114.78 | -229.79 | -267.55 | 12.91 | 228.74 |
Free Cash Flow Per Share | 0.03 | 0.27 | -0.54 | -0.63 | 0.04 | 0.63 |
Dividend Per Share | 0.463 | 0.463 | 0.213 | 0.235 | 0.211 | - |
Dividend Growth | 117.47% | 117.47% | -9.36% | 11.37% | - | - |
Gross Margin | 80.82% | 82.86% | 85.68% | 87.94% | 91.22% | 91.14% |
Operating Margin | 0.08% | 5.57% | 0.69% | 9.15% | 23.77% | 27.69% |
Profit Margin | 4.80% | 29.73% | 15.08% | 16.67% | 24.45% | 25.17% |
Free Cash Flow Margin | 1.23% | 10.49% | -24.79% | -17.92% | 0.71% | 16.77% |
EBITDA | 90.59 | 137.49 | 65.2 | 184.38 | 468.91 | 402.47 |
EBITDA Margin | 9.20% | 12.56% | 7.03% | 12.35% | 25.71% | 29.50% |
D&A For EBITDA | 89.78 | 76.51 | 58.81 | 47.72 | 35.43 | 24.75 |
EBIT | 0.8 | 60.98 | 6.39 | 136.66 | 433.49 | 377.72 |
EBIT Margin | 0.08% | 5.57% | 0.69% | 9.15% | 23.77% | 27.69% |
Effective Tax Rate | - | 9.67% | - | - | 6.67% | 13.78% |
Revenue as Reported | 984.29 | 1,094 | 927.08 | 1,493 | 1,824 | 1,364 |
Advertising Expenses | - | - | - | 1 | 3.71 | 3.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.